Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease

被引:0
|
作者
Fu, Yu [1 ,2 ]
Hua, Yuxin [1 ]
Alam, Naqash [2 ]
Liu, Enqi [2 ]
机构
[1] Lanzhou Univ, Sch Life Sci, MOE Key Lab Cell Act & Stress Adaptat, Lanzhou 730000, Peoples R China
[2] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, 76 Yanta West Rd, Xian 710061, Peoples R China
关键词
MASLD; animal model; physiology; pathology; HIGH-FAT DIET; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; CHOLINE-DEFICIENT; CARBON-TETRACHLORIDE; HIGH-FRUCTOSE; MURINE MODEL; BODY-WEIGHT; MOUSE MODEL; OBESE GENE;
D O I
10.3390/nu16183120
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative term to NAFLD. MASLD is a globally recognized chronic liver disease that poses significant health concerns and is frequently associated with obesity, insulin resistance, and hyperlipidemia. To better understand its pathogenesis and to develop effective treatments, it is essential to establish suitable animal models. Therefore, attempts have been made to establish modelling approaches that are highly similar to human diet, physiology, and pathology to better replicate disease progression. Here, we reviewed the pathogenesis of MASLD disease and summarised the used animal models of MASLD in the last 7 years through the PubMed database. In addition, we have summarised the commonly used animal models of MASLD and describe the advantages and disadvantages of various models of MASLD induction, including genetic models, diet, and chemically induced models, to provide directions for research on the pathogenesis and treatment of MASLD.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
    Zhou, Da
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2024, 137 (22) : 2687 - 2696
  • [2] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025, : 669 - 677
  • [3] Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
    Zhou Da
    Fan Jiangao
    中华医学杂志英文版, 2024, 137 (22)
  • [4] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [5] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [6] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [7] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [8] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [9] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [10] Active role of the immune system in metabolic dysfunction-associated steatotic liver disease
    Mori, Taizo
    Yoshio, Sachiyo
    Kakazu, Eiji
    Kanto, Tatsuya
    GASTROENTEROLOGY REPORT, 2024, 12